Par, UCB Pharma Settle Keppra Patent Fight

Law360, New York (August 24, 2011, 2:18 PM EDT) -- UCB Pharma SA and Par Pharmaceutical Inc. on Monday settled a suit Par had filed in Pennsylvania seeking a court declaration that two UCB patents were invalid and not infringed by Par's proposed generic version of the epilepsy drug Keppra.

Solely for the purpose of enforcing the parties' agreement, Par conceded that the two patents-in-suit were valid and enforceable and would be infringed by the marketing of the Par proposed generic levetiracetam extended-release tablets, according to a stipulation and order signed by U.S. District Judge Mitchell...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.